Department of Internal Medicine, National Taiwan University College of Medicine, Taipei, Taiwan.
Diabetes Care. 2012 Feb;35(2):278-80. doi: 10.2337/dc11-1449. Epub 2011 Dec 30.
The association between pioglitazone and bladder cancer has not been investigated in Asians. We aimed to investigate this association.
A total of 1,000,000 individuals were randomly sampled from the National Health Insurance database, and incident cases of bladder cancer during the period from 1 January 2006 to 31 December 2009 were analyzed among 54,928 patients with type 2 diabetes and without previous bladder cancer.
Among 165 incident case subjects, 10 (0.39%) were ever users and 155 (0.30%) were never users of pioglitazone (adjusted hazard ratio in full model 1.305 [95% CI 0.661-2.576]). All bladder cancer in ever users occurred within a duration of therapy <24 months, suggesting an early effect of pioglitazone on bladder cancer or late use of pioglitazone in high-risk patients.
The association between pioglitazone and bladder cancer was not significant. However, confirmation of this finding is required because of the possible lack of statistical power owing to the small number of events.
吡格列酮与膀胱癌之间的关联尚未在亚洲人群中进行过研究。本研究旨在对此关联进行探讨。
从国家健康保险数据库中随机抽取了 100 万人作为样本，对 2006 年 1 月 1 日至 2009 年 12 月 31 日期间患有 2 型糖尿病且无膀胱癌既往史的 54928 例患者进行了分析，观察其间膀胱癌的发病情况。
在 165 例新发膀胱癌病例中，10 例（0.39%）为吡格列酮曾用者，155 例（0.30%）为从未使用者（全模型校正后 HR 为 1.305[95%CI 0.661-2.576]）。所有曾用者的膀胱癌均发生在治疗时间<24 个月内，提示吡格列酮对膀胱癌具有早期作用，或在高危患者中存在延迟使用吡格列酮的情况。
吡格列酮与膀胱癌之间的关联并不显著。但是，由于事件数量较少，可能存在统计学效能不足的问题，因此需要进一步确认这一发现。
